Prosecution Insights
Last updated: April 19, 2026

Examiner: WILLIS, DOUGLAS M

Tech Center 1600 • Art Units: 1624

This examiner grants 83% of resolved cases

Performance Statistics

82.7%
Allow Rate
+22.7% vs TC avg
1821
Total Applications
+19.4%
Interview Lift
766
Avg Prosecution Days
Based on 1781 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
16.7%
§102 Novelty
7.8%
§103 Obviousness
50.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18256629 Process for the preparation of 4-(3,5-difluorophenyl)-N-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine Non-Final OA Hoffmann-La Roche Inc.
18076383 NOVEL IMIDAZOPYRAZINE DERIVATIVES Final Rejection Hoffmann-La Roche Inc.
18072223 COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT Non-Final OA Northwestern University
18315472 N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Non-Final OA Dana-Farber Cancer Institute, Inc.
18313652 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS Non-Final OA Merck Patent GmbH
18279556 METHOD OF TREATING A CONDITION USING A THERAPEUTICALLY EFFECTIVE DOSE OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-YL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE Non-Final OA Janssen Pharmaceutica NV
17997091 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES Non-Final OA Pfizer Inc.
17971318 STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES Non-Final OA Atea Pharmaceuticals, Inc.
18647249 PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE Non-Final OA Cardurion Pharmaceuticals, Inc.
18267235 IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS Non-Final OA UCB Biopharma SRL
18458292 THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF Non-Final OA Chugai Seiyaku Kabushiki Kaisha
18168874 JAK INHIBITOR COMPOUND AND USE THEREOF Non-Final OA HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD.
17786504 THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT Final Rejection TAIHO PHARMACEUTICAL CO., LTD.
18001148 ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES Non-Final OA Saint Louis University
17997642 ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES Non-Final OA SYDDANSK UNIVERSITET
18269670 FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF Non-Final OA Xizang Haisco Pharmaceutical Co., Ltd.
18497879 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS Non-Final OA Escient Pharmaceuticals, Inc.
18487254 Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide Final Rejection Acerta Pharma B.V.
18344167 Pyrazolopyrimidine compounds as kinase Inhibitors Final Rejection Principia Biopharma Inc.
18263656 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS Non-Final OA ACCUTAR BIOTECHNOLOGY INC.
18066275 PYRAZINE COMPOUNDS AND USES THEREOF Non-Final OA Dizal (Jiangsu) Pharmaceutical Co., Ltd.
18279377 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor Non-Final OA Provincial Health Services Authority
18229476 SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Non-Final OA IMMUNOGEN, INC.
18270781 PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB Non-Final OA OLON S.P.A.
18261896 PROCESS FOR MAKING IBRUTINIB Non-Final OA Synthon B.V.
18220475 METHOD FOR PREVENTING AND/OR TREATING LIVER FIBROSIS BY USING 6-METHOXYBENZOXAZOLINONE AND COIX LACHRYMA-JOBI L. EXTRACT COMPRISING 6-METHOXYBENZOXAZOLINONE Non-Final OA Taichung District Agricultural Research and Extension Station, Ministry of Agriculture
18024236 MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS Non-Final OA Centessa Pharmaceuticals (UK) Limited
18259762 PYRIDINE-2-AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Non-Final OA BEIJING SYNTHETIC VACCINE BIOSCIENCES CO., LTD
18210766 KINASE MODULATORS AND METHODS OF USE THEREOF Non-Final OA SUNDANCE BIOSCIENCES, INC.
18257027 COMPOUND CONTAINING 1,3-BENZODIOXOL STRUCTURE AND PREPARATION METHOD AND USE THEREOF Non-Final OA XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month